Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Cefazolin in High vs Low Weight Subjects
NCT05309304Phase 1Completed
- Sponsor
- Baxter
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of cefazolin in surgical site infection (SSI) (2 arms), sponsored by Baxter. Primary endpoints: Area under the curve at Day 1, Maximum concentration at Day 1 and 2 more. Started Feb 2022; status: completed.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05309304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309304.